Immediate Impact
49 standout
Citing Papers
Tumor biomarkers for diagnosis, prognosis and targeted therapy
2024 Standout
Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents
2024 Standout
Works of Hun-Mo Ryoo being referenced
RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial
2015
Randomized phase II trial of sunitinib four-week on and two-week off versus two-week on and one-week off in metastatic clear cell type renal cell carcinoma: RESTORE trial.
2015
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Hun-Mo Ryoo | 102 | 95 | 105 | 107 | 30 | 291 | |
| Rika Kasajima | 132 | 67 | 124 | 84 | 37 | 334 | |
| Yasufumi Matsuda | 69 | 62 | 91 | 57 | 26 | 251 | |
| Yuliya Linhares | 91 | 92 | 75 | 66 | 27 | 273 | |
| Firoz Ahmad | 60 | 136 | 114 | 57 | 37 | 284 | |
| Caroline Weipert | 90 | 56 | 57 | 103 | 34 | 275 | |
| Donna Bucci | 97 | 128 | 101 | 63 | 18 | 316 | |
| C. Massard | 84 | 47 | 137 | 127 | 38 | 317 | |
| A. Chalmers | 164 | 114 | 90 | 90 | 28 | 290 | |
| Klaus Hoeffken | 93 | 56 | 42 | 53 | 22 | 249 | |
| Gary Zeger | 154 | 42 | 59 | 148 | 19 | 308 |
All Works
Loading papers...